Skip to main content
Home / News / Certara’s Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19

Certara’s Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19

Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology

Princeton, N.J., July 23, 2021: Certara, a global leader in biosimulation, today announced that its Vaccine Simulator accurately predicted that eight weeks was the optimal timing between the first and second dose of COVID-19 vaccines. The Pitch study conducted at Oxford University in the United Kingdom confirmed Certara’s Vaccine Simulator prediction, which was released six months ago.  Current dosing for the Pfizer-BioNTech and Moderna vaccines are spaced three and four weeks apart, respectively. 

“The Pitch study results further validate that Certara’s biosimulation technology is a powerful, predictive tool to understand how vaccines and COVID-19 therapies work, enabling us to get dosing regimens right the first time,” said William F. Feehery, CEO of Certara. “We continue to invest in innovation to fight this ongoing pandemic and benefit global health.”

The Certara Vaccine Simulator, based upon the Company’s quantitative systems pharmacology (QSP) technology, integrates diverse inputs, including bioinformatics and in-vitro assays, to develop sophisticated models that answer ‘what-if’ scenarios to determine the best dosing strategies for various patient cohorts, such as the elderly and children. The Simulator has been used by a number of global pharmaceutical companies and its findings have been presented to regulatory agencies, including a U.S. Food and Drug Administration (FDA) workshop in June of 2021.

“Our Vaccine Simulator allows us to address critical questions on efficacy and safety of dosing regimens for different types of patients for COVID-19 as well as in other therapeutic areas. We have recently calibrated and validated our Vaccine Simulator with very large clinical data sets and added additional vaccine types,” said Piet van der Graaf, PharmD, PhD, senior vice president of QSP at Certara. “We also already have models to determine the optimal timing of COVID-19 vaccine boosters, what is the best way to mix and match vaccines, and what is required to maintain efficacy against COVID-19 variants.”

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:

David Deuchler
Gilmartin Group

Media Contact:

Ariane Lovell
Finn Partners